SCHEMBL3765211

SCHEMBL3765211

Clc1nc2ccccn2c1-c1ccnc(Nc2cccc(N3CCOCC3)c2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 2/20 0.61
CDK2 P24941 6/20 0.60
LCK P06239 4/20 0.60
KDR P35968 4/20 0.60
MAP4K5 Q9Y4K4 4/20 0.60
CSF1R P07333 3/20 0.60
FGFR1 P11362 3/20 0.60
TAOK1 Q7L7X3 3/20 0.60
PLK4 O00444 2/20 0.60
PRKD3 O94806 2/20 0.60
SRC P12931 2/20 0.60
FLT1 P17948 2/20 0.60
FGFR3 P22607 2/20 0.60
SYK P43405 2/20 0.60
GSK3A P49840 2/20 0.60
GSK3B P49841 2/20 0.60
AURKB Q96GD4 2/20 0.60
SLK Q9H2G2 2/20 0.60
MAP3K20 Q9NYL2 2/20 0.60
CHEK1 O14757 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759773 0.83 IGF1R (0.63) IGF1RMAPK8EGFRERBB2MAPK10
SCHEMBL3761539 0.83 IGF1R (0.63) CDK2KITFLT3IRAK4JAK2
SCHEMBL3762095 0.81 CDK2 (0.54) CAMK2DCDK2LCKKDRMAP4K5
SCHEMBL3760568 0.81 CDK2 (0.74) CAMK2DCDK2LCKKDRMAP4K5
SCHEMBL1789167 0.81 IGF1R (0.71) CDK2LCKKDRMAP4K5CSF1R
SCHEMBL1871349 0.81 IGF1R (0.64) CDK2LCKKDRMAP4K5CSF1R
SCHEMBL1788491 0.80 IGF1R (0.61) CAMK2DCDK2LCKKDRMAP4K5
SCHEMBL1788634 0.79 IGF1R (0.62) CDK2LCKKDRMAP4K5CSF1R
SCHEMBL3759323 0.79 CDK2 (0.56) CAMK2DCDK2LCKKDRMAP4K5
SCHEMBL1789150 0.78 IGF1R (0.67) CAMK2DCDK2LCKKDRMAP4K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435436-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-07-30 EP disclosed
US-8354422-B2 Pyrimidine inhibitors of kinase activity ABBOTT LABORATORIES INC. (US) 2013-01-15 US disclosed
WO-2010138576-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity IGF1R, CDK2, TK1 CAMK2D 904/4885CDK2 2/4885LCK 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.